Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.92%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.48 per share when it actually produced a loss of $0.41, delivering a surprise of 14.58%.Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-37581 ACLARIS THERAPEUTICS, INC. Incorporated under the Laws of the I.R.S. Employer Identification No. State of Delaware 46-0571712 701 Lee Road, Suite 103 Wayne, PA 19087 (484) 324-7933 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Tradin ...

Shares of Aclaris Therapeutics, Inc. (ACRS) were up 25.4% on Jan 16 after the company announced the appointment of Neal Walker as the new interim chief executive officer (CEO). Walker will replace Douglas Manion, who stepped down from his role with immediate effect. He also served as the president of the company and was a member of the board of directors.Walker is currently serving as the chairman of the company and is also a co-founder. He held the role of Aclaris' CEO until 2022.Along with the leadership ...

- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its busines ...

About this content About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.  Read more About the publisher Pr ...

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports "Soft" Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigationa ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aclaris Therapeutics (ACRS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aclaris Therapeutics is a member of our Medical group, which includes 1077 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the st ...

7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37581 Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-0571712 (State or Othe ...

7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37581 Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-0571712 (State or Other Jur ...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Robert Doody - Head of Investor Relations Douglas Manion - Chief Executive Officer Gail Cawkwell - Senior Key Executive Joseph Monahan - Chief Scientific Officer Kevin Balthaser - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Thomas Smith - SVB Securities Alexander Thompson - Stifel Roger Song - Jefferies Dipesh Patel - W ...